About Innoviva
Innoviva is a company based in Brisbane (United States) founded in 1996. The company has 127 employees as of December 31, 2024. Innoviva has completed 2 acquisitions, including Entasis Therapeutics and La Jolla Pharmaceutical. Innoviva offers products and services including Royalty Portfolio and Critical Care Platform. Innoviva operates in a competitive market with competitors including Landos Biopharma, Theron Pharma, Maibo Pharmaceutical, Arcede Pharma and Arum Therapeutics, among others.
- Headquarter Brisbane, United States
- Employees 127 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Innoviva, Inc.
-
Annual Revenue
$372.51 M (USD)14.88as on Dec 31, 2024
-
Net Profit
$23.39 M (USD)-86.98as on Dec 31, 2024
-
EBITDA
$206.72 M (USD)38.19as on Dec 31, 2024
-
Latest Funding Round
$261 M (USD), Post-IPO
Apr 01, 2022
-
Investors
Goldman Sachs
& 1 more
-
Employee Count
127
as on Dec 31, 2024
-
Investments & Acquisitions
Entasis Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Innoviva
Innoviva is a publicly listed company on the NASDAQ with ticker symbol INVA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Innoviva
Innoviva offers a comprehensive portfolio of products and services, including Royalty Portfolio and Critical Care Platform.
Manages royalties from healthcare products and therapies
Supports growth in infectious disease treatments and assets
People of Innoviva
Unlock access to complete
Unlock access to complete
Funding Insights of Innoviva
Investors in Innoviva
Innoviva has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs and Moelis & Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked | |
|
Advisory services in M&A, restructuring, and capital raising are offered.
|
Locked | Locked | Locked |
Investor details for Innoviva
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Innoviva
Innoviva has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Entasis Therapeutics and La Jolla Pharmaceutical.
Investment portfolio details for Innoviva
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecules for drug-resistant bacterial infections are developed.
|
Locked | Locked | 2015 | Locked | |
|
Developer of therapies for treating hemochromatosis & beta thalassemia
|
Locked | Locked | 1989 | Locked |
Complete acquisition details for Innoviva
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Innoviva
Detailed financials for Innoviva
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Innoviva Comparisons
Peer comparison for Innoviva
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Innoviva
Innoviva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Landos Biopharma, Theron Pharma, Maibo Pharmaceutical, Arcede Pharma and Arum Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics for autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialty drugs for chronic respiratory diseases are developed.
|
|
| Locked | Locked | Locked |
Drugs for cancer and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Develops patent-protected drugs for chronic respiratory diseases via collaborations and research.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and respiratory diseases are developed.
|
Detailed competitors of Innoviva
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Innoviva
Complete news archive for Innoviva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innoviva
Innoviva was founded in 1996 and raised its 1st funding round 21 years after it was founded.
Innoviva is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
Pavel Raifeld is the current CEO of Innoviva.
As of Dec 31, 2024, the latest employee count at Innoviva is 127.
Annual revenue of Innoviva is $372.51M as on Dec 31, 2024.
Innoviva was founded in 1996 in Brisbane, United States, within the pharmaceutical sector focused on respiratory conditions. Prescription drugs are developed through in-licensing partnerships with Glaxo Group. Operations center on inhaled therapies, including RelvarBreoEllipta as a combination respiratory drug and AnoroEllipta as a dual bronchodilator, both targeted at managing chronic obstructive pulmonary disease.
Innoviva's top competitors include Landos Biopharma, Maibo Pharmaceutical and Theron Pharma.
Innoviva offers Royalty Portfolio and Critical Care Platform.
Yes, Innoviva is publicly traded on NASDAQ under the ticker symbol INVA.
Innoviva has made 2 acquisitions, including Entasis Therapeutics, and La Jolla Pharmaceutical.
Innoviva has 2 investors. Key investors include Goldman Sachs, and Moelis & Company.
The ticker symbol of Innoviva is INVA on NASDAQ.